Meeting
2013 Genitourinary Cancers Symposium
Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer.
Authors
Helmy M. Guirgis
University of California, Irvine, Irvine, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 200)
DOI
10.1200/jco.2013.31.6_suppl.200
Abstract #
200
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Quality Care Symposium
Application of a novel method weighing drug costs against survival in castrate-resistant prostate cancer cancer.
First Author: Helmy M. Guirgis
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 Genitourinary Cancers Symposium
Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Rana R. McKay
Poster
2018 Genitourinary Cancers Symposium
Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).
First Author: Justine Ku